Sector
PharmaceuticalsOpen
₹114.35Prev. Close
₹115.26Turnover(Lac.)
₹29.36Day's High
₹115.89Day's Low
₹113.5952 Week's High
₹176.5952 Week's Low
₹96.8Book Value
₹37.76Face Value
₹10Mkt Cap (₹ Cr.)
406.76P/E
49.39EPS
2.31Divi. Yield
0Here are some of the stocks that may see significant price movement today: Reliance Industries, HCLTech, Sunteck Realty, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 42.16 | 48.13 | 28.69 | 28.69 |
Preference Capital | 1.08 | 1.08 | 0.78 | 0.71 |
Reserves | 57.17 | 28.3 | 15.75 | -24.28 |
Net Worth | 100.41 | 77.51 | 45.22 | 5.12 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 164.34 | 62.26 | 33.67 | 41.68 |
yoy growth (%) | 163.95 | 84.92 | -19.21 | -46.56 |
Raw materials | -30.86 | -23.52 | -15.48 | -21.53 |
As % of sales | 18.77 | 37.77 | 45.99 | 51.66 |
Employee costs | -16.21 | -13.02 | -10.57 | -10.89 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 64.9 | -16.96 | -24.24 | -12.69 |
Depreciation | -15.38 | -8.04 | -5.64 | -6.3 |
Tax paid | -20.33 | 3.93 | -1.19 | 0.38 |
Working capital | 29.28 | 5.11 | -23.18 | 16.67 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 163.95 | 84.92 | -19.21 | -46.56 |
Op profit growth | 575.87 | -742.93 | 333.98 | -102.37 |
EBIT growth | 887.98 | -262.21 | 7.28 | -127.49 |
Net profit growth | -375.97 | -72.81 | 390.71 | 5,718.25 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 138.5 | 111.19 | 93.07 | 194.08 | 86.25 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 138.5 | 111.19 | 93.07 | 194.08 | 86.25 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 2.23 | 1.45 | 3.4 | 2.09 | 1.56 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
KUNAL NARENDRA GANDHI
Executive Director & CFO
Yogesh B Shah
Non-Exec. & Independent Dir.
Dhara P. Shah
Chairman & Independent Directo
Babulal Jain
Non Executive Director
Prashant Godha
Non Executive Director
Shashil Mendonsa
Company Sec. & Compli. Officer
Shekhar R Singh
Additional Director
Archana Yadav
4801/B & 4802/A,
GIDC Industrial Estate,
Gujarat - 393002
Tel: 91-02646-221422/220549
Website: http://www.lykalabs.com
Email: [email protected]; [email protected]
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai - 400083
Tel: 91-22-28515644/5606
Website: www.sharexindia.com
Email: [email protected]
Summary
Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. 83. It also added a range of ayurvedic...
Read More
Reports by Lyka Labs Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.